Primum non nocere: a critical analysis of early intervention clinical trials in smoldering multiple myeloma.

Authors

Harsh Parmar, Noa Biran, Pooja Phull, Kimberly Doucette, James Di Palma-Grissi, Joseph Franz, David Vesole, David Siegel

Published in

Frontiers in oncology. Volume 16. Pages 1834686. Epub Sep 22, 2026.

Abstract

The approach to the management of smoldering multiple myeloma has changed over the years, which has evolved from observation towards early therapeutic intervention. Yet, a comprehensive examination of several key clinical trials reveals methodological challenges and limitations, ranging from inconsistent risk stratification of SMM to biased interpretations of results due to artifactual inflation of benefit arising from lead-time bias. Intervention for patients with a largely asymptomatic disease needs to be re-assessed carefully, where toxicities arising from treatment are not well justified. Until a more precise risk stratification is developed, the principle of "primum non nocere" (first, do no harm) should curb enthusiasm for early intervention in a condition in which a substantial number of patients will remain progression-free without treatment.

PMID:
42840630
Bibliographic data and abstract were imported from PubMed on 07 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.